企业介绍 中英
康臣药业集团主要从事化学合成、原料药、小容量注射剂、颗粒剂、片剂、丸剂、口服液（中药前处理及提取）、口服溶液等多种剂型药品的生产经营活动，并以先进的科技水平建立了完善的质量保证体系，集团各生产基地先后顺利通过国家GMP认证。广东康臣药业集团在广州、内蒙等地均拥有大型工业园区及多条世界一流的制药生产线，其设备和技术水平在行业中处于领先水平。
Consun Pharmaceutical deals mainly with the production and operation of drugs in a variety of dosage forms, such as chemically synthetic drugs, raw material drugs, small volume injections, granules, tablets, pills, oral liquids (pretreatment and extraction of traditional Chinese drugs) and oral solutions, and has established a sound quality assurance system with advanced technology level. All production bases of the Group have passed the state GMP certification successfully in succession. Guangdong Consun Pharmaceutical has large industrial parks and a number of world-class pharmaceutical production lines in Guangzhou and Inner Mongolia, which are leading in the industry in equipment and technology.
康臣药业始终追求产品的高科技、高效能、高品质，与国内外多家权威医药科研机构成立了“康臣肾病药物研究中心”，具备卓越的产品开发能力。其中，集团肾病系列产品中的主导产品“尿毒清颗粒（无糖型）”作为国家卫生部首个批准的治疗早中期慢性肾功能衰竭的专科药品，填补了中药制剂治疗CRF的空白，获国家专利、国家中药保护品种；“钆喷酸葡胺注射液”（MRI造影剂）填补国内核磁共振诊断成像用药空白，属国家二类新药，为康臣药业首家生产的药品。以上药品均已列入国家基本医疗保险药品和军队合理医疗药品目录。
In a constant pursuit for hi-tech, highly effective and high-quality products, Consun Pharmaceutical has founded the Consun Drug Research Center for Renal Diseases together with several prestigious domestic and foreign medical research institutions, possessing excellent ability to develop products. The Niaoduqing Granules (sugar free), the main product in the Group’s kidney drug series and the first specific drug for early and medium-stage chronic renal failure (CRF) approved by the Ministry of Health of the People’s Republic of China, have filled up a gap in CRF treatment with traditional Chinese medicinal preparations, and become a national patent and a traditional Chinese drug protected by the state. The Gadopentetate Meglumine Injection (MRI contrast medium) has filled up a domestic gap in NMR diagnostic imaging, and is a national Class-II new drug and a drug first produced by Consun Pharmaceutical. The above drugs have been included into the Catalogue of Drugs for Basic National Medical Insurance and the Catalogue of Drugs for Reasonable Military Medical Treatment.
康臣药业集团已建立覆盖全国31个省市自治区的营销体系。在巩固和发展国内市场的同时，康臣药业不断开拓国际市场，目前康臣药业各类产品已销售至港、澳、台、东南亚、日本、美国、加拿大等国家和地区。www.en-ch.com
Consun Pharmaceutical has established a marketing network that covers 31 provinces, municipalities and autonomous regions of China. While strengthening and developing its domestic market, Consun Pharmaceutical is always exploring the international market. By now, Consun Pharmaceutical products have been sold to many countries and regions, including Hong Kong, Macao, Taiwan, Southeast Asia, Japan, the U.S. and Canada.
2008年3月31日，康臣药业吸收联想弘毅1.8亿入股资金，战略重点从原来主要从事产品经营转向产品经营、品牌经营与资本经营相结合，标志康臣药业发展驶入快车道。
On March 31, 2008, Consun Pharmaceutical absorbed equity funds of RMB180 million Yuan from Lenovo Hony, and refocused its strategy from product operation mainly to a combination of product, brand and capital operations, indicating the beginning of its rapid development.